Legend Biotech Corporation (LEGN)

45.30 +0.88 (+1.98%) 收市：04:00PM EDT

Legend Biotech Corporation

2101 Cottontail Lane
Somerset, NJ 08873
United States
732 317 5050
https://www.legendbiotech.com

版塊: Healthcare
行業: Biotechnology
全職員工: 1,800

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Ying Huang Ph.D.	CEO & Director	無	無	1973
Ms. Lori A. Macomber CPA	Chief Financial Officer	無	無	1971
Mr. Doug Wallace	Vice President of Global Operations	無	無	無
Dr. Guowei Fang Ph.D.	Chief Scientific Officer & Head of Business Development	無	無	無
Joanne Choi	Senior Manager of Investor Relations	無	無	無
Mr. James Pepin J.D.	General Counsel	無	無	無
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	無	無	無
Ms. Elaine Qian	VP & Global Head of Human Resources	無	無	無
Dr. Yuhong Qiu Ph.D.	Senior Vice President of Global Regulatory Affairs	無	無	無
Mr. Steven J. Gavel	Senior Vice President of Commercial Development, US & Europe	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

公司管治

截至 無 止，Legend Biotech Corporation 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。